OnKure Therapeutics, Inc.
$ 4.61
3.48%
14 Apr - close price
- Market Cap 60,847,000 USD
- Current Price $ 4.61
- High / Low $ 4.70 / 4.45
- Stock P/E N/A
- Book Value 4.11
- EPS -4.40
- Next Earning Report 2026-05-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.45 %
- ROE -0.74 %
- 52 Week High 4.75
- 52 Week Low 1.70
About
OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company is headquartered in Boulder, Colorado.
Analyst Target Price
$20.20
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-13 | 2025-11-07 | 2025-08-13 | 2025-05-05 | 2025-03-11 | 2024-11-06 | 2024-08-13 | 2024-05-07 | 2024-03-28 | 2023-11-13 | 2023-08-10 | 2023-05-11 |
| Reported EPS | -0.99 | -1.09 | -1.14 | -1.1863 | -1.37 | -0.86 | -1.6041 | -2.5212 | -7.0477 | -5.678 | -6.4639 | -6.034 |
| Estimated EPS | -1.152 | -1.198 | -1.248 | -1.38 | -0.87 | -0.9 | None | None | None | None | None | None |
| Surprise | 0.162 | 0.108 | 0.108 | 0.1937 | -0.5 | 0.04 | 0 | 0 | 0 | 0 | 0 | 0 |
| Surprise Percentage | 14.0625% | 9.015% | 8.6538% | 14.0362% | -57.4713% | 4.4444% | None% | None% | None% | None% | None% | None% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-05 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.81 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OKUR
2026-03-03 02:52:38
OnKure Therapeutics has completed its merger with Reneo Pharmaceuticals and a concurrent $65 million private placement, with the combined company now trading on Nasdaq as OKUR. This transaction provides OnKure with approximately $139 million in cash, extending its operational runway into Q4-2026, and is focused on advancing its lead program, OKI-219, for PI3KαH1047R mutations in breast cancer with early clinical data expected in Q4-2024. Nicholas A. Saccomano, Ph.D., will lead the new entity as President and CEO.
2025-05-06 00:08:36
OnKure Therapeutics (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on precision medicines for cancers driven by PI3Kα mutations, with its lead candidate OKI-219 in Phase 1 clinical trials for advanced solid tumors. The company is also developing a broader PI3Kα-focused pipeline and exploring applications in vascular malformations. OKUR's recent financial highlights include a market cap of $54.4 million, trailing twelve-month net income of -$59.5 million, and a current ratio indicating strong liquidity.
2024-10-11 09:28:37
Cormorant Asset Management has strategically acquired 189,571.7 shares of Reneo Pharmaceuticals Inc. at $18.2 per share, marking a new holding and a 14.98% stake in the company. This investment, by the Boston-based firm known for its focus on healthcare and biotechnology, diversifies its portfolio within the sector. Reneo Pharmaceuticals, a clinical-stage company developing treatments for rare genetic mitochondrial diseases, faces financial challenges despite its innovative approach.
2024-10-07 07:31:36
OnKure and Reneo Pharmaceuticals have successfully completed their merger, with the combined company now operating as OnKure Therapeutics. The new entity's shares will trade on Nasdaq under the ticker "OKUR" following an all-stock deal and a $65 million private placement. The merger aims to accelerate the development of OnKure's mutant-specific PI3Kα inhibitor portfolio, extending its cash runway through Q4 2026 for multiple clinical readouts.
2024-10-04 08:08:49
OnKure Therapeutics announced the completion of its merger with Reneo Pharmaceuticals and a concurrent $65 million private placement. The combined company, operating as OnKure Therapeutics, will focus on advancing its pipeline of PI3Kα inhibitors, particularly OKI-219 for breast cancer, with an expected cash runway into Q4-2026. Shares will begin trading on Nasdaq under the new ticker symbol "OKUR" on October 7, 2024.
2024-05-29 16:56:00
Brodsky & Smith announced investigations into potential breaches of fiduciary duties by the boards of Avangrid, SilverBow Resources, Reneo Pharmaceuticals, and Perficient. These investigations concern the fairness of proposed acquisitions or mergers for shareholders. Shareholders are encouraged to contact Brodsky & Smith for discussions regarding these investigations.
